First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02339207
• Date of registration: 18/12/2014
• Prospective Registration: Yes
• Primary sponsor: Alios Biopharma Inc.
• Public title: First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
• Scientific title: A Randomized, Double-blind, Placebo-controlled, First-in-human, 3 Part Study of Orally Administered AL-335 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection
• Date of first enrolment: December 31, 2014
• Target sample size: 112
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02339207
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
• Phase: Phase 1

Countries of recruitment

France, Georgia, Moldova, Republic of

Key inclusion & exclusion criteria

Inclusion Criteria:

- Subject has provided written consent.

- In the investigator's opinion, the subject is able to understand and comply with
protocol requirements, instructions, and protocol stated restrictions and is likely to
complete the study as planned.

- Subject is in good health as deemed by the investigator, based on the findings of a
medical evaluation including medical history, physical examination, laboratory tests,
and ECG.

- Male or female, 18-60 years of age for HV and 18-65 years of age for subjects with
CHC.

- Body mass index (BMI) 18-32 kg/m2, inclusive, for HV and 18-35 kg/m2, inclusive, for
subjects with CHC. The minimum weight is 50 kg in both populations. No more than 25%
of patients in any cohort may be enrolled with a BMI = 30 kg/m2.

- A female subject is eligible to participate in this study if she is of non
childbearing potential (defined as females with a documented tubal ligation, bilateral
oophorectomy, or hysterectomy) or postmenopausal (defined as 12 months of spontaneous
amenorrhea and follicle stimulating hormone (FSH) level within the laboratory's
reference range for postmenopausal females). A post-menopausal female receiving
hormone replacement therapy who is willing to discontinue hormone therapy 28 days
before study drug dosing and agrees to remain off hormone replacement therapy for the
duration of the study may be eligible for study participation.

- If male, subject is surgically sterile or practicing specific forms of birth control
(as outline in Section 6.2.9) until 90 days after the end of the study.

Additional inclusion criteria for subjects with CHC infection:

- Documentation of Genotype 1 HCV infection for greater than 6 months at dosing

- Screening HCV RNA viral load = 105 IU/mL using a sensitive quantitative assay, such as
COBAS® Taqman® HCV Test 2.0

Exclusion Criteria:

1. Clinically significant cardiovascular, respiratory, renal, gastrointestinal,
hematologic, neurologic, thyroid, or any other medical illness or psychiatric
disorder, as determined by the Investigator and/or Sponsor's Medical Monitor.

2. Positive test for HAV IgM, HBsAg, or HIV Ab. In Parts 1 and 2 positive HCV serology is
exclusionary.

3. Any condition that, in the opinion of the investigator, would compromise the study's
objectives or the well-being of the subject or prevent the subject from meeting the
study requirements.

4. Participation in an investigational drug trial or having received an investigational
vaccine within 30 days or 5 half lives (whichever is longer) prior to study
medication.

5. Clinically significant abnormal ECG findings. Particularly, a history or family
history of prolonged QT syndrome (e.g., torsade de pointes) or sudden cardiac death;
or a corrected QT interval (QTc) > 450 milliseconds for male subjects and >470
milliseconds for female subjects at the Screening Visit.

6. Clinically significant blood loss or elective blood donation of significant volume
(i.e., > 500 mL) within 60 days of first dose of study drug; > 1 unit of plasma within
7 days of first dose of study drug.

7. Abnormal heart rate, respiratory rate, temperature or blood pressure values outside of
the normal range (evaluated in a semi-recumbent or recumbent position after 5 minutes
of rest). One repeat measurement after an additional 5 minutes of rest is permitted.

8. Evidence of active infection (other than CHC infection in subjects enrolled in Part
3).

9. Unwilling to abstain from alcohol for 48 hours prior to the start of dosing through
the study completion visit.

10. History of regular alcohol intake > 7 units per week of alcohol for females and > 14
units per week for males (one unit is defined as 10 g alcohol) within 3 months of
screening visit.

11. For healthy subjects (Parts 1-2), history of regular use of tobacco (i.e., =10
cigarettes per day) or nicotine-containing products within 3 months of the screening
visit. For subjects with CHC infection, history of regular use of tobacco- or
nicotine-containing products is allowed.

12. The subject has a positive pre-study drug screen. A minimum list of drugs that will be
screened for includes amphetamines, barbiturates, cocaine, opiates, cannabinoids,
phencyclidine (PCP) and benzodiazepines. Subjects with CHC may be included if they
have a positive result for cannabinoids at screening. However, they must be willing to
abstain from cannabinoid use throughout the duration of the study.

13. In Parts 1-2, the use of concomitant medications, including prescription, over the
counter medications, or herbal medications within 14 days prior to the first dose of
study medication is excluded, unless approved by the Sponsor's Medical Monitor. PRN
use of a nonsteroidal anti inflammatory drug (NSAID) is permitted.

14. For subjects in Part 3, the use of prescription and over the counter medications
deemed necessary to maintain the health status of the subject are permitted, if
approved by the Sponsor's Medical Monitor. PRN NSAID use is permitted. Further
guidance for the use of prior medication in subjects with CHC can be found in Section
5.7.

15. Subjects must not have received any drug known to be a strong inducer or inhibitor of
CYP450 enzymes within 2 weeks prior to study drug dosing (Appendix C).

16. Exposure to more than four new investigational entities within 12 months prior to the
first dosing day.

17. Abnormal biochemistry or hematology laboratory results obtained at screening. Elevated
bilirubin in subjects with suspected Gilbert's disease is allowed.

Additional exclusion criteria for subjects with CHC infection:

18. History of clinical hepatic decompensation, e.g., variceal bleeding, spontaneous
bacterial peritonitis, ascites, hepatic encephalopathy or active jaundice

19. Liver biopsy within two years or Fibroscan evaluation within 6 months prior to
randomization that demonstrates cirrhosis (Knodell score >3, Metavir score > 3, Ishak
score > 4). Fibroscan liver stiffness score > 10.5 kPa.

20. Prior treatment for CHC

21. Serum alanine aminotransferase (ALT) concentration >5 x ULN

22. Alpha Fetoprotein (AFP) is = ULN, unless the absence of a hepatic mass or lesion is
demonstrated by ultrasound within the screening period.



Age minimum: 18 Years
Age maximum: 60 Years
Gender: All

Health Condition(s) or Problem(s) studied

Chronic Hepatitis C

Intervention(s)

Drug: AL-335 matching placebo

Drug: AL-335

Primary Outcome(s)

Safety Data: Number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results [Time Frame: From screening to Day 8 (SAD/FE) and Day 21 (MAD)]

Secondary Outcome(s)

Single Dose PK: Cmax, tmax, t1/2, CL/F and Vz/F (for AL-335 only), AUC0-inf or AUClast [Time Frame: From dosing to Day 8 visit for each SAD/FE cohort]

Multiple Dose PK: Cmax, tmax, t1/2, AUClast and AUC0 tau [Time Frame: From dosing to final study visit (21 days) for each cohort]

Hepatitis C viral levels [Time Frame: From screening to final study visit (21 days) for each cohort]

Secondary ID(s)

AL-335-601

Source(s) of Monetary Support

Please refer to primary and secondary sponsors